登录 | 注册    关注公众号  
微信公众号
搜索
 > 【NKG2A & CD94】

NKG2A & CD94信息

英文名称:NK cell lectin-like receptor subfamily C member 1
中文名称:自然杀伤细胞凝集素样受体亚家族C成员1
靶点别称:CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
上市药物数量:0
临床药物数量:5
最高研发阶段:临床三期

NKG2A & CD94分子别名

NKG2A & CD94

NKG2A & CD94分子背景

CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

NKG2A & CD94临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Monalizumab NN-8765; IPH-2201; NNC-0141-0000-0100 临床三期 Innate Pharma, 诺和诺德制药 结直肠癌, 腺癌, 非小细胞肺癌, 慢性淋巴细胞白血病, 食管鳞状细胞癌, 小细胞癌, 口腔癌, 鳞状细胞癌, 食道腺癌, 炎性疾病, 头颈癌, 女性生殖系统癌症, 乳腺癌, 类风湿关节炎, 小细胞肺癌, 食道癌, 胃癌, 头颈部鳞状细胞癌, 实体瘤, 血液肿瘤 详情
BMS-986315 BMS-986315 临床二期 百时美施贵宝 实体瘤, 非小细胞肺癌 详情
S-095029 S-095029 临床二期 Institut De Recherches Internationales Servier 实体瘤, 食道癌, 胃癌, 错配修复基因缺陷型肿瘤, 高微卫星不稳定性癌症, 非小细胞肺癌 详情
BRY-805 BRY805; BRY-805 临床一期 浙江博锐生物制药有限公司 实体瘤 详情
HY000102 HY-0102; HY-000102 临床一期 上海怀越生物科技有限公司 实体瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定